Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
R-Pharm
R-Pharm
Bristol-Myers Squibb
Mayo Clinic
Shanghai Miracogen Inc.
Amgen
Massachusetts General Hospital
Sun Yat-sen University
Oscotec Inc.
Sun Yat-sen University
National Institutes of Health Clinical Center (CC)
Shanghai Miracogen Inc.
ImmunityBio, Inc.
NRG Oncology
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Gilead Sciences
University of Southern California
Mayo Clinic
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Rakuten Medical, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Memorial Sloan Kettering Cancer Center
Peking Union Medical College
Hokkaido University Hospital
Groupe Oncologie Radiotherapie Tete et Cou
Memgen, Inc.
Merck Sharp & Dohme LLC
GERCOR - Multidisciplinary Oncology Cooperative Group
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NuCana plc
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Hummingbird Bioscience
Thomas Jefferson University
Dana-Farber Cancer Institute
Sun Yat-sen University
University of Pittsburgh
Sir Run Run Shaw Hospital
Shanghai JMT-Bio Inc.
City of Hope Medical Center
MediLink Therapeutics (Suzhou) Co., Ltd.